Having trouble accessing articles? Reset your cache.

Abilify aripiprazole regulatory update

The U.K.'s NICE issued a preliminary appraisal for Abilify ariprazole from Bristol-Myers and Otsuka to treat schizophrenia in patients ages 15-17 years. In the

Read the full 245 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE